We aim to develop treatment options for those diseases that have an impact on all our lives and directly benefit patients' survival and overall quality of life.
Following a publication in the PNAS, the Federal German Ministry for Education and Research backs PROSION Therapeutics' research with a €1m grant for the in-vivo validation of Ena/VASP as target proteins for metastatic cancer therapy.
The Federal German Ministry for Economics and Technology backs the translation of the cutting-edge research into a biotech company through its EXIST programme - founding of PROSION GmbH follows by the end of 2020.
PROSION Therapeutics secures a €2.5m (non-dilutive) grant from the highly competitive European Innovation Council (EIC) Accelerator for the deployment of its platform technology and to further boost its lead program in oncology.
PROSION Therapeutics secures Seed Investment from renowned early-stage Deep-Tech investor Freigeist Capital to further accelerate the deployment of its platform technology and lead program in oncology.
PROSION Therapeutics is eligible for an equity co-investment of up to €15m from the European Investment Bank (EIB).